Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MGX

Metagenomi Inc.

May 01 • 04:00PM ET

7.04

Dollar change +0.02
Percentage change 0.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI SCHA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	49.54%	Shs Outstand	37.47M	Perf Week	4.30%
Market Cap	263.79M	Forward P/E	-	EPS next Y	-2.76	Insider Trans	5.10%	Shs Float	18.91M	Perf Month	-31.38%
Income	-	PEG	-	EPS next Q	-0.77	Inst Own	0.94%	Short Float	4.79%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	85.51%	Inst Trans	-	Short Ratio	4.22	Perf Half Y	-
Book/sh	-3.62	P/B	-	EPS next Y	4.89%	ROA	-	Short Interest	0.91M	Perf Year	-
Cash/sh	7.24	P/C	0.97	EPS next 5Y	-	ROE	-	52W Range	6.50 - 12.74	Perf YTD	-31.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-44.74%	Beta	-
Dividend TTM	-	Quick Ratio	4.04	Sales past 5Y	3569.20%	Gross Margin	-	52W Low	8.31%	ATR (14)	0.79
Dividend Ex-Date	-	Current Ratio	4.04	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	36.11	Volatility	12.12% 10.19%
Employees	236	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.20
Option/Short	No / Yes	LT Debt/Eq	0.21	EPS Q/Q	-	Payout	-	Rel Volume	0.41	Prev Close	7.02
Sales Surprise	6.89%	EPS Surprise	50.11%	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	214.53K	Price	7.04
SMA20	-16.20%	SMA50	-30.99%	SMA200	-32.02%	Trades		Volume	88,913	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

Today 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
04:35PM	Loading…
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc.

Upgrade your FINVIZ experience